What's happening
This bill expands optometrists' authority to use and prescribe a broader range of topical pharmaceutical agents for the eye and adnexa.
Why it matters
Broader treatment flexibility. The bill removes narrow lists of allowed drug classes, letting optometrists use and prescribe any FDA-approved topical pharmaceutical agent for the eye and its surrounding tissues (adnexa), not just specific agents previously named in law. This could allow for more up-to-date, patient-tailored care as new drugs are developed.
Expanded scope for diagnosis and treatment. By including the “adnexa” (structures around the eye, like eyelids and tear ducts), optometrists may be able to treat a wider range of eye-related conditions, potentially reducing the need for referrals to ophthalmologists for certain issues.
Streamlined certification and mobility. The law clarifies and simplifies certification requirements for optometrists trained in other states, making it easier for experienced professionals to practice in New York and potentially improving patient access to care.
Potential for faster, more convenient eye care. Patients may benefit from quicker access to necessary medications through their optometrist, rather than needing to see another provider for prescriptions that were previously restricted, potentially reducing delays and improving outcomes.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expand Use of Eye Medications
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Eye Medication Use
In Senate Committee · Higher Education · Sponsor John Liu
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9830
IN ASSEMBLY
April 11, 2024
Introduced by M. of A. PAULIN -- read once and referred to the Committee on Higher Education
AN ACT to amend the education law, in relation to the use of topical pharmaceutical agents
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraphs (d), (e) and (f) of subdivision 1 of section 7101-a of the education law, paragraph (d) as added by chapter 517 of the laws of 1995 and paragraphs (e) and (f) as amended by chapter 506 of the laws of 2021, are amended to read as follows:
(d) Diagnostic pharmaceuticals. Diagnostic pharmaceuticals shall mean those drugs which shall be limited to topical applications [to the surface of the eye] for the purpose of diagnostic examination of the eye [and shall be limited to:
(i) Anesthetic agents;
(ii) Mydriatics;
(iii) Cycloplegics;
(iv) Miotics;
(v) Disclosing agents and other substances used in conjunction with these drugs as part of a diagnostic procedure] and adnexa.
(e) Topical therapeutic pharmaceutical agents. Topical therapeutic pharmaceutical agents shall mean those drugs which shall be limited to topical application [to the surface of the eye] for therapeutic purposes [and shall be limited to:
(i) antibiotic/antimicrobials;
(ii) decongestants/anti-allergenics;
(iii) non-steroidal anti-inflammatory agents;
(iv) steroidal anti-inflammatory agents;
(v) antiviral agents;
(vi) hyperosmotic/hypertonic agents;
(vii) cycloplegics;
(viii) artificial tears and lubricants; and
(ix) immunosuppressive agents] of the eye and adnexa.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14942-02-4
(f) Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension. Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension shall mean those drugs which shall be limited to topical application [to the surface] for therapeutic purposes of the eye and [shall be limited to:
(i) beta blockers;
(ii) alpha agonists;
(iii) direct acting cholinergic agents;
(iv) prostaglandin analogs; and
(v) carbonic anhydrase inhibitors] adnexa.
§ 2. Paragraph (e) of subdivision 4 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995 and as relettered by chapter 506 of the laws of 2021, is amended to read as follows:
(e) The provisions of paragraphs (a) and (b) of this subdivision shall not apply to (i) graduates of an appropriate program approved by the department who have successfully passed the examination on the use of diagnostic and therapeutic [drugs] agents and who graduated subsequent to January first, nineteen hundred ninety-three; or (ii) optometrists who have been certified for at least five years to use [phase one] topical therapeutic agents and [phase two drugs] therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension in another jurisdiction, have demonstrated such use in independently managed patients, and have been licensed in accordance with section seventy-one hundred four of this chapter. Provided, however, no optometrist exempt under this paragraph shall be permitted to use [phase one] topical therapeutic pharmaceutical agents or [phase two] therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension prior to the general authorization provided to optometrists licensed in this state.
§ 3. The opening paragraph of paragraph (b) and paragraph (c) of subdivision 10 of section 7101-a of the education law, as amended by chapter 506 of the laws of 2021, are amended to read as follows:
Those optometrists having been certified for topical therapeutic pharmaceutical agents shall be authorized to use and prescribe all topical therapeutic pharmaceutical agents [specified in paragraph (e) of subdivision one of this section], which are FDA approved and commercially available for topical use.
(c) Those optometrists having been certified for therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension shall be authorized to use and prescribe therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension [specified in paragraph (f) of subdivision one of this section], which are FDA approved and commercially available.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.